Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation

Psychopharmacology

Volumn 234, Issue 4, 2017, Pages 525-533

  Ma, Min ^a   Ren, Qian ^a   Yang, Chun ^a   Zhang, Ji chun ^a   Yao, Wei ^a   Dong, Chao ^a   Ohgi, Yuta ^b   Futamura, Takashi ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Brexpiprazole; Fluoxetine; Inflammation; Spine; SSRI

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BREXPIPRAZOLE; FLUOXETINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN MAPPING; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; DENTATE GYRUS; DEPRESSION; DRUG POTENTIATION; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; IMMOBILITY; INFLAMMATION; INFRALIMBIC CORTEX; MAJOR DEPRESSION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRELIMBIC CORTEX; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECTS; METABOLISM; NERVE CELL;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DENDRITIC SPINES; DEPRESSION; FLUOXETINE; INFLAMMATION; MALE; MICE; NEURONS; PREFRONTAL CORTEX; QUINOLONES; SIGNAL TRANSDUCTION; THIOPHENES;

EID: 84995380118     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4483-7     Document Type: Article

References (51)

1. Barbee JG, Conrad EJ, Jamhour NJ (2004) The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 65:975–981
2. Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME (2014) Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 39:2549–2559
3. Björkholm C, Jardemark K, Schilstrom B, Svensson TH (2015) Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat. Eur Neuropsychopharmacol 25:1842–1847
4. 2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today (Barc) 51:397–414
5. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56
6. Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K (2016) Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. See comment in PubMed Commons belowPharmacol Biochem Behav 144:7–12
7. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446–457
8. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68–72
9. Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: a historical overview and future directions. Psychiatry Clin Neurosci 64:341–357
10. Hashimoto K (2015a) Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as diagnostic biomarkers for major depressive disorder and bipolar disorder. Eur Arch Psychiatry Clin Neurosci 265:83–84
11. Hashimoto K (2015b) Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 16:7796–7801
12. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioral effect of selective serotonin reuptake inhibitors. Bri J Pharmacol 144:695–702
13. 2A receptors. Eur Neuropsychopharmacol 25:505–511
14. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894–902
15. Ma M, Ren Q, Zhang JC, Hashimoto K (2014) Effects of brilliant blue G on serum tumor necrosis factor-α levels and depression-like behavior in mice after lipopolysaccharide administration. Clin Psychopharmacol Neurosci 12:31–36
16. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T (2014a) Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:589–604
17. Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, Stensbøl TB, Bundgaard C, Arnt J, Kikuchi T (2014b) Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:605–614
18. McEwen BS (2007) Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87:873–904
19. McKeage K (2016) Adjunctive brexpiprazole: a review in major depressive disorder. CNS Drugs 30:91–99
20. Miller AH, Raison CL (2015) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22–34
21. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM (2014) Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry 19:791–800
22. Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials Am J Psychiatry 166:980–991.
23. Nestler EJ, Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151–1159
24. O’Connor JC, Lawson MA, André C, Moreau M, Lestage J, Castanon N, Kelley KW, Dantzer R (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 14:511–522
25. Ohgi Y, Futamura T, Hashimoto K (2015) Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 15:206–221
26. Ohgi Y, Futamura T, Kikuchi T, Hashimoto K (2013) Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 103:853–859
27. Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K, ADMIRE Study Group (2015) Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg depression rating scale and Hamilton rating scale for depression item analyses of the aripiprazole depression multicenter efficacy study. Psychiatry Clin Neurosci 69:34–42
28. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC (2015) Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry 172:1251–1258
29. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA (2005) Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66:1326–1330
30. Papakostas GI, Shelton RC, Smith J, Fava M (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68:826–831
31. Rogóz Z (2013) Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol Rep 65:1536–1544
32. Remus JL, Dantzer R (2016) Inflammation models of depression in rodents: relevance to psychotropic drug discovery. Int J Neuropsychopharmacol 19:pyw028
33. Ren Q, Ma M, Ishima T, Morisseau C, Yang J, Wagner KM, Zhang JC, Yang C, Yao W, Dong C, Han M, Hammock BD, Hashimoto K (2016) Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci U S A 113:E1944–E1952
34. Ren Q, Ma M, Yang C, Zhang JC, Yao W, Hashimoto K (2015) BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms. Transl Psychiatry 5:e666
35. Shelton RC, Papakostas GI (2008) Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 117:253–259
36. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70–75
37. Shirayama Y, Yang C, Zhang JC, Ren Q, Yao W, Hashimoto K (2015) Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol 25:2449–2458
38. Stahl SM (2016) Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr 21:1–6
39. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ (2015) Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol 25:1532–1543
40. Svensson TH, Björkholm C, Konradsson-Geuken A, Jardemark K, Marcus MM (2016) The novel atypical antipsychotic brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism. Abstract at the Monitoring Molecules in Neuroscience 2016. May 29 – June 2, Gothenburg, Sweden
41. Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, McQuade RD, Carson WH, Nyilas M, Sanchez R, Eriksson H (2015a) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 76:1224–1231
42. Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015b) Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 76:1232–1240
43. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K (2015a) Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol 18:pyu121
44. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015b) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632
45. Yao W, Zhang JC, Dong C, Zhuang C, Hirota S, Inanaga K, Hashimoto K (2015) Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 136:7–12
46. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M, Kimura A, Iyo M, Hashimoto K (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7:e42676
47. 1A receptors. Pharmacol Biochem Behav 124:245–249
48. Yoshimi N, Futamura T, Hashimoto K (2015) Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol 25:356–364
49. Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (2015a) Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychophamacol 18:pyu077
50. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Hashimoto K (2015b) Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology 232:4325–4335
51. Zhang JC, Yao W, Hashimoto K (2016) Brain-derived neurotrophic factor (BDNF)–TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol 14:721–731